Immunodeficiency Clinical Trials

9 recruiting

Immunodeficiency Trials at a Glance

95 actively recruiting trials for immunodeficiency are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Not Applicable with 23 trials, with the heaviest enrollment activity in Bethesda, Pittsburgh, and Cape Town. Lead sponsors running immunodeficiency studies include National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), and Merck Sharp & Dohme LLC.

Browse immunodeficiency trials by phase

Treatments under study

About Immunodeficiency Clinical Trials

Looking for clinical trials for Immunodeficiency? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immunodeficiency trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immunodeficiency clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 95 trials

Recruiting
Phase 1Phase 2

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

X-linked Severe Combined Immunodeficiency (XSCID)
National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT01306019
Recruiting

Genetic Analysis of Immune Disorders

ImmunodeficiencyGATA2DOK 8+2 more
National Institute of Allergy and Infectious Diseases (NIAID)5,000 enrolled1 locationNCT00001467
Recruiting
Phase 2

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

MDSImmunodeficiencyGATA2
National Cancer Institute (NCI)144 enrolled1 locationNCT01861106
Recruiting

Genetic Basis of Immunodeficiency

Severe Combined Immunodeficiency
National Heart, Lung, and Blood Institute (NHLBI)100 enrolled1 locationNCT00055172
Recruiting
Phase 2

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Lymphoproliferative DisordersImmune System DiseasesCommon Variable Immunodeficiency+2 more
National Cancer Institute (NCI)354 enrolled2 locationsNCT02579967
Recruiting

The Mechanistic Biology of Primary Immunodeficiency Disorders

Primary Immunodeficiency Disorders
National Institute of Allergy and Infectious Diseases (NIAID)2,500 enrolled2 locationsNCT03394053
Recruiting
Phase 2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC84 enrolled24 locationsNCT04375800
Recruiting
Phase 2

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Hematopoietic Stem Cell TransplantationImmunodeficiency
National Cancer Institute (NCI)54 enrolled1 locationNCT05027945
Recruiting
Phase 2Phase 3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled47 locationsNCT07266831
Recruiting

Harm Reduction in HIV Primary Care for PLWH Who Use Drugs

Substance UseHuman Immunodeficiency VirusStigma, Social
University of Pittsburgh768 enrolled3 locationsNCT05404750
Recruiting
Phase 1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

Human Immunodeficiency Virus
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT06819176
Recruiting

NIAID Centralized Sequencing Protocol

Primary ImmunodeficiencyAtopy
National Institute of Allergy and Infectious Diseases (NIAID)20,000 enrolled2 locationsNCT03206099
Recruiting
Not Applicable

Adaptation and Implementation of an Evidence-based Approach to Advance HIV Prevention and Care

HIV (Human Immunodeficiency Virus)StigmaContinuum of Care
University of California, Los Angeles80 enrolled1 locationNCT07495059
Recruiting

Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies

Primary Immunodeficiency
National Institute of Allergy and Infectious Diseases (NIAID)3,000 enrolled3 locationsNCT03610802
Recruiting

Natural History of Bronchiectasis

Cystic FibrosisBronchiectasisAutoimmune Disease+1 more
National Heart, Lung, and Blood Institute (NHLBI)900 enrolled1 locationNCT00943514
Recruiting

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myelogenous Leukemia+7 more
Wake Forest University Health Sciences2,000 enrolled1 locationNCT01890486
Recruiting
Phase 4

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

Smoking CessationHuman Immunodeficiency Virus (HIV)
New York University500 enrolled1 locationNCT06598397
Recruiting
Phase 1

HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong

Human Immunodeficiency VirusHuman Immunodeficiency Virus I Infection
Immuno Cure Holding (HK) Limited22 enrolled1 locationNCT07530198
Recruiting
Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled78 locationsNCT07044297
Recruiting

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Atopic DermatitisPsoriasisPrimary Immunodeficiency+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT04864886